Neflamapimod + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
Conditions
Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
Trial Timeline
Aug 1, 2025 → Oct 1, 2026
NCT ID
NCT07033481About Neflamapimod + Placebo
Neflamapimod + Placebo is a phase 2 stage product being developed by CervoMed for Nonfluent Variant Primary Progressive Aphasia (nfvPPA). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07033481. Target conditions include Nonfluent Variant Primary Progressive Aphasia (nfvPPA).
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07033481 | Phase 2 | Recruiting |
| NCT06987643 | Phase 2 | Recruiting |
| NCT05869669 | Phase 2 | Completed |